NEC Corporation has introduced its FonesVisuas Test, an innovative blood test designed to predict disease risk, through Royal Healthcare, a Singapore-based medical institution and subsidiary of Sojitz Corporation. This advancement aims to address the global rise in lifestyle-related diseases and dementia by providing advanced predictive diagnostics.
The World Health Organization highlights the urgency for such diagnostics, as lifestyle-related diseases and dementia continue to increase worldwide. Concurrently, data from the Organisation for Economic Co-operation and Development identifies cancer and cardiovascular diseases as leading causes of mortality globally, further emphasizing the need for proactive health management solutions.
Royal Healthcare, located in Singapore's medical hub, Novena, offers personalized, high-quality health screening services. The integration of the FonesVisuas Test into their offerings marks a significant advancement. This test analyzes proteins reflecting dynamic physiological changes, allowing it to predict the risk of developing conditions such as dementia, heart attack, lung cancer, chronic kidney disease, and prostate cancer over the next several years from just a small blood sample.
By combining the FonesVisuas Test with conventional health checkups, Royal Healthcare aims to guide individuals who are not yet ill but also not in optimal health toward lifestyle improvements. This approach seeks to prevent future illness and enhance quality of life.
NEC plans to expand the availability of the FonesVisuas Test internationally, particularly in the Asia-Pacific region, reinforcing its commitment to advancing global healthcare standards.
Comments are closed.